!ID 0000001
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!5
!v701!1
!v709!text
!v708!58
!v704!<p align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>INFORMES    T&Eacute;CNICOS INSTITUCIONAIS</b></font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000002
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!6
!v701!2
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000003
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!7
!v701!3
!v709!text
!v708!58
!v704!<p><a name="top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Desafios    da tuberculose diante da resist&ecirc;ncia microbiana</b></font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000004
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!8
!v701!4
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000005
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!9
!v701!5
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>The challenges    of tuberculosis on antimicrobial resistance</b></font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000006
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!10
!v701!6
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000007
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!11
!v701!7
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000008
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!12
!v701!8
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Instituto Clemente    Ferreira, Coordenadoria de Controle de Doen&ccedil;as, Secretaria de Estado    da Sa&uacute;de</b></font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000009
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!13
!v701!9
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc;ncia    | Correspondence</a></font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000010
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!14
!v701!10
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000011
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!15
!v701!11
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000012
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!16
!v701!12
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A tuberculose (TB)    permanece sendo enorme desafio para a sa&uacute;de p&uacute;blica. Apesar de    existir grande conhecimento tecnol&oacute;gico da doen&ccedil;a, outros fatores    ainda impedem que se atinjam as metas propostas para o seu controle, como pobreza,    desnutri&ccedil;&atilde;o, a co-infec&ccedil;&atilde;o com HIV.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000013
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!17
!v701!13
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Desde 1993, a TB    tornou-se prioridade para a Organiza&ccedil;&atilde;o Mundial da Sa&uacute;de    (OMS) e, em 2000, para o Brasil. O or&ccedil;amento atual para o controle da    TB &eacute; 14 vezes maior que em 2002, por&eacute;m ainda insuficiente.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000014
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!18
!v701!14
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Segundo a OMS,    o Brasil est&aacute; em 16&#186; lugar entre os 22 pa&iacute;ses priorit&aacute;rios    para controle da TB, i.e., com maior n&uacute;mero de casos TB no mundo. Por&eacute;m,    n&atilde;o estamos entre os pa&iacute;ses de maior n&uacute;mero de casos de    TB multidrogarresistente (TBMDR).</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000015
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!19
!v701!15
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A incid&ecirc;ncia    de TB no Brasil tem decrescido desde a d&eacute;cada de 1950, quando foram notificados    160.000 casos novos; na d&eacute;cada de 1990 foram 110.000 casos; e no &uacute;ltimo    levantamento, em 2009, foram notificados 72.000 casos, n&uacute;mero considerado    ainda bastante elevado.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000016
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!20
!v701!16
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A meta da OMS &eacute;    de, at&eacute; 2015, curar 85% e detectar 70% dos casos. Entretanto, o Brasil    ainda est&aacute; atrasado em rela&ccedil;&atilde;o a essa meta.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000017
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!21
!v701!17
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">As caracter&iacute;sticas    da transmiss&atilde;o da TB por bacilo sens&iacute;vel e por bacilo resistente    s&atilde;o as mesmas: transmiss&atilde;o aer&oacute;gena, ocorrendo em aglomera&ccedil;&otilde;es    humanas e tendo rela&ccedil;&atilde;o direta com a imunidade baixa. A grande    diferen&ccedil;a &eacute; que o bacilo resistente tem menor virul&ecirc;ncia,    comprovada em experimento de 1953,<a name="topa"></a><a href="#backa">ª</a>    em que cobaias inoculadas com bacilos resistentes a isoniazida produziam menor    n&uacute;mero de les&otilde;es e mortes. Outro estudo<a name="topb"></a><a href="#backb"><sup>b</sup></a>    de 1999 mostrou que contatos de focos resistentes adoeciam menos do que os contatos    de focos drogas sens&iacute;veis, talvez porque alguns genes resistentes a drogas    reduzem a virul&ecirc;ncia do bacilo. Estudo de 2003<a name="topc"></a><a href="#backc"><sup>c</sup></a>    mostrou, com aux&iacute;lio da epidemiologia molecular, que bacilos resistentes    a isoniazida apresentavam uma muta&ccedil;&atilde;o no gene KatG (22%-64%) respons&aacute;vel    pela produ&ccedil;&atilde;o de catalase e peroxidase. Essas enzimas s&atilde;o    fundamentais para a vida dos bacilos, o que os tornava menos virulentos.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000018
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!22
!v701!18
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A TB &eacute; cur&aacute;vel    em praticamente 100% dos casos novos, sens&iacute;veis aos medicamentos anti-TB,    desde que tratada adequadamente com terapia medicamentosa. Hoje no Brasil curam-se    69% dos casos de TB bacilos sens&iacute;veis. Por&eacute;m, a taxa de abandono    &eacute; alta, ao redor de 13%, o que resulta em surgimento da resist&ecirc;ncia    adquirida. Ao ser transmitida, a resist&ecirc;ncia adquirida leva ao aparecimento    da resist&ecirc;ncia prim&aacute;ria.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000019
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!23
!v701!19
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Em 1979, o sistema    de tratamento para a TB adotado no Brasil era composto pelo esquema I (2RHZ/4RH)    para os casos novos, esquema I refor&ccedil;ado (2RHZE/4RHE) para retratamentos,    esquema II (2RHZ/7RH) para a forma meningoencef&aacute;lica e esquema III (3SZEEt/9EEt)    para a fal&ecirc;ncia dos anteriores.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000020
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!24
!v701!20
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Dois Inqu&eacute;ritos    Nacionais de Resist&ecirc;ncia aos F&aacute;rmacos Antituberculosos, realizados    entre 1995-1997 e 2007-2008, evidenciaram aumento da resist&ecirc;ncia prim&aacute;ria    &agrave; isoniazida (de 4,4% para 6,0%) e aumento da resist&ecirc;ncia &agrave;    associa&ccedil;&atilde;o rifampicina-isoniazida, o que levou &agrave; necessidade    de mudan&ccedil;as. Em 2009, o Programa Nacional de Controle da Tuberculose    foi revisto pelo seu Comit&ecirc; T&eacute;cnico Assessor, resultando em padroniza&ccedil;&atilde;o    do esquema b&aacute;sico com introdu&ccedil;&atilde;o do quarto f&aacute;rmaco,    o etambutol. Este foi introduzido na fase intensiva, nos dois primeiros meses    de tratamento, com o objetivo de diminuir a transmissibilidade e proteger a    rifampicina, evitando aparecimento de resist&ecirc;ncia. Foram extintos o esquema    I refor&ccedil;ado e o esquema III, sendo solicitados cultura, identifica&ccedil;&atilde;o,    teste de sensibilidade para todos os casos de retratamento e adotado esquema    padronizado para multi-resist&ecirc;ncia (associa&ccedil;&atilde;o de cinco    drogas incluindo um aminoglicos&iacute;deo e uma quinolona) (<a href="/img/revistas/rsp/v45n5/itssf01.jpg">Figura    1</a>) ou esquemas especiais individualizados, segundo a combina&ccedil;&atilde;o    de resist&ecirc;ncias apresentadas pelo teste de sensibilidade. &Eacute; um    grande desafio realizar o teste de sensibilidade para todos os pacientes de    retratamento devido &agrave; necessidade de uma rede de laborat&oacute;rio capacitada    em todo o territ&oacute;rio nacional.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000021
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!25
!v701!21
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">No Brasil a co-infec&ccedil;&atilde;o    TB-HIV em pacientes com TB bacilos sens&iacute;veis &eacute; de 12%;<a name="topd"></a><a href="#backd"><sup>d</sup></a>    em casos de TBMDR-HIV essa taxa &eacute; menor (7%).<a name="tope"></a><a href="#backe"><sup>e</sup></a></font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000022
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!26
!v701!22
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">O tratamento da    TB em pessoas infectadas pelo HIV segue as mesmas recomenda&ccedil;&otilde;es    para os n&atilde;o infectados, tanto nos esquemas quanto na dura&ccedil;&atilde;o    total do tratamento. A pronta solicita&ccedil;&atilde;o do teste anti-HIV e    a agilidade de seu resultado em pacientes com TB &eacute; fundamental para o    correto manuseio do tratamento da co-infec&ccedil;&atilde;o TB-HIV.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000023
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!27
!v701!23
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Para melhorar a    ades&atilde;o ao tratamento, com melhor &iacute;ndice de cura e conseq&uuml;entemente    diminui&ccedil;&atilde;o do aparecimento de cepas resistentes, a OMS prop&ocirc;s    o uso da estrat&eacute;gia do tratamento diretamente observado (DOTS) em 1999:</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000024
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!28
!v701!24
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Compromisso governamental    com o Programa Nacional de Controle da Tuberculose e aumento dos financiamentos.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000025
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!29
!v701!25
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Tratamento diretamente    observado (TDO), com supervis&atilde;o das tomadas e suporte aos pacientes.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000026
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!30
!v701!26
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Bacteriologia de    qualidade dos sintom&aacute;ticos respirat&oacute;rios para melhor detec&ccedil;&atilde;o    de casos.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000027
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!31
!v701!27
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Suprimentos de    drogas e gerenciamento de registros, notifica&ccedil;&otilde;es de casos e controle    do Programa.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000028
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!32
!v701!28
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Monitorar registro,    avaliar o sistema e o impacto das medidas propostas.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000029
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!33
!v701!29
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">O Instituto Clemente    Ferreira (ICF) &eacute; uma unidade de refer&ecirc;ncia terci&aacute;ria em    Pneumologia e Tisiologia da Secretaria da Sa&uacute;de do Estado de S&atilde;o    Paulo que atua especificamente no atendimento de casos de TBMDR, efeitos adversos    ao tratamento, TB extrapulmonar e casos de micobacterioses n&atilde;o tuberculosas.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000030
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!34
!v701!30
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A maioria dos pacientes    referenciados para ICF mora distante, e para ser feito o TDO foi implementada    a Supervis&atilde;o Cooperada, em que uma unidade de sa&uacute;de pr&oacute;xima    ao domic&iacute;lio do paciente se responsabiliza em receber o paciente ou ir    at&eacute; seu domic&iacute;lio, caso o paciente n&atilde;o tenha condi&ccedil;&otilde;es    de se deslocar. Isso permite avaliar melhor a situa&ccedil;&atilde;o global    dos pacientes e familiares, possibilitando melhor acolhimento dessas fam&iacute;lias    (<a href="#f2">Figura 2</a>).</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000031
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!35
!v701!31
!v709!text
!v708!58
!v704!<p><a name="f2"></a></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000032
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!36
!v701!32
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000033
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!37
!v701!33
!v709!text
!v708!58
!v704!<p align="center"><img src="/img/revistas/rsp/v45n5/itssf02.jpg"></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000034
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!38
!v701!34
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000035
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!39
!v701!35
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A TBMDR no mundo    ganhou &ecirc;nfase na d&eacute;cada de 1980 ap&oacute;s um surto em Nova Iorque,    quando grandes esfor&ccedil;os foram realizados para o controle da doen&ccedil;a    naquele pa&iacute;s.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000036
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!40
!v701!36
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">No per&iacute;odo    de 2000 a 2004 a OMS e o Centers for Disease Control and Prevention (CDC) avaliaram    14.706 amostras de escarro provenientes de 49 pa&iacute;ses e perceberam que    no grupo de pacientes com TBMDR resistentes a isoniazida e rifampicina existiam    casos com resist&ecirc;ncia a isoniazida, rifampicina e outras drogas, o que    veio ser chamada de Tuberculose Extensivamente Resistente (TBXDR). A TBXDR &eacute;    definida como resist&ecirc;ncia a isoniazida e rifampicina mais pelo menos uma    droga injet&aacute;vel (amicacina, capreomicina ou canamicina) e uma quinolona.    Certas regi&otilde;es do mundo evidenciavam ter 20% dos casos de multi-resist&ecirc;ncia    com padr&atilde;o XDR.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000037
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!41
!v701!37
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">O ICF realizou    levantamento de casos de TB no per&iacute;odo de 1994 a 2007. Foram notificados    10.306 casos, dos quais 733 (7%) eram TBMDR. Dentre os casos de TBMDR foram    encontrados 18 (2%) casos de TBXDR, 70% deles resistentes a ofloxacina, cujo    progn&oacute;stico era muito ruim, mas houve casos de cura.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000038
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!42
!v701!38
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Alguns casos permaneceram    bacil&iacute;feros e clinicamente est&aacute;veis, tornando-se focos de transmiss&atilde;o    de bacilos resistentes e gerando um grave problema de sa&uacute;de p&uacute;blica.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000039
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!43
!v701!39
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Em 2008, segundo    estimativas da OMS, havia 400.000 casos novos de TBMR no mundo, metade deles    na &Iacute;ndia e na China. Os pa&iacute;ses com menores recursos s&atilde;o    os respons&aacute;veis pelo maior n&uacute;mero de casos, agravado ainda pela    grande incid&ecirc;ncia local de HIV (<a href="/img/revistas/rsp/v45n5/itssf03.jpg">Figura 3</a>).</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000040
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!44
!v701!40
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">No Brasil, no per&iacute;odo    2000-2008, foram notificados 4.064 casos de TBMR, 95% deles por resist&ecirc;ncia    adquirida e o restante por resist&ecirc;ncia prim&aacute;ria. Somado a isso,    o fato de todos os casos de TBXDR do ICF serem provenientes do grupo de TBMR    sugere que o programa de controle da TB n&atilde;o est&aacute; sendo suficientemente    eficaz. A taxa de cura de TBMR varia de 50% a 70%, sendo provavelmente pior    nos casos de TBXDR e mais ainda quando associado &agrave; HIV.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000041
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!45
!v701!41
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Acredita-se que    o n&uacute;mero de casos de TBMR no Brasil esteja subestimado. Novos e r&aacute;pidos    testes diagn&oacute;sticos seriam muito importantes para identificar mais casos,    instituir tratamento adequado e impedir a transmiss&atilde;o de TBMR.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000042
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!46
!v701!42
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">O Brasil participa    de um projeto para uso de dois novos testes moleculares, Xpert MTB/RIF, para    detec&ccedil;&atilde;o r&aacute;pida e precoce de resist&ecirc;ncia a rifampicina,    e GenoType TBDRplus, para resist&ecirc;ncia a rifampicina e isoniazida. Os resultados    ser&atilde;o avaliados tanto no aspecto cl&iacute;nico-diagn&oacute;stico quanto    no econ&ocirc;mico, para poss&iacute;vel implanta&ccedil;&atilde;o no Sistema    &Uacute;nico de Sa&uacute;de.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000043
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!47
!v701!43
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">A preven&ccedil;&atilde;o    deve ser feita com acesso a diagn&oacute;stico r&aacute;pido, tratamento adequado    e dispon&iacute;vel para todos, manejo adequado dos casos, suporte para boa    ader&ecirc;ncia, implanta&ccedil;&atilde;o de medidas de bio-seguran&ccedil;a,    maior intera&ccedil;&atilde;o entre programa de TB-HIV e quimioprofilaxia. Os    desafios s&atilde;o novas drogas e novos regimes terap&ecirc;uticos, novos e    melhores testes diagn&oacute;sticos, padroniza&ccedil;&atilde;o internacional    do teste de sensibilidade para drogas de segunda linha.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000044
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!48
!v701!44
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">O aumento da incid&ecirc;ncia    de TBMR e TBXDR no mundo exige uma abordagem multidisciplinar. Essas formas    de resist&ecirc;ncia s&atilde;o conseq&uuml;&ecirc;ncia de um programa inadequado    de controle de TB, diagn&oacute;stico tardio e recursos insuficientes para controle    de infec&ccedil;&atilde;o.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000045
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!49
!v701!45
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000046
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!50
!v701!46
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000047
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!51
!v701!47
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top"><img src="/img/revistas/rsp/v45n5/seta.jpg" border="0"></a>    <b>Correspond&ecirc;ncia | Correspondence:</b>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000048
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!52
!v701!48
!v709!text
!v708!58
!v704!<br>   Instituto Clemente Ferreira    ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000049
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!53
!v701!49
!v709!text
!v708!58
!v704!<br>   R. da Consola&ccedil;&atilde;o, 717    ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000050
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!54
!v701!50
!v709!text
!v708!58
!v704!<br>   01301-000 S&atilde;o Paulo, SP, Brasil</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000051
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!55
!v701!51
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000052
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!56
!v701!52
!v709!text
!v708!58
!v704!<p>&nbsp;</p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000053
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!57
!v701!53
!v709!text
!v708!58
!v704!<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Texto de difus&atilde;o    t&eacute;cnico-cient&iacute;fica da Secretaria de Sa&uacute;de do Estado de    S&atilde;o Paulo.    ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000054
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!58
!v701!54
!v709!text
!v708!58
!v704!<br>   <a name="backa"></a><a href="#topa">a</a> Middlebrook G, Cohn ML. Some observations    on the pathogenicity of isoniazid-resistance variants of tuberculosis bacilli.    <i>Science.</i> 1953;118(3063):297-9. DOI: 10.1126/science.118.3063.297    ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000055
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!59
!v701!55
!v709!text
!v708!58
!v704!<br>   <a name="backb"></a><a href="#topb">b</a> van Soolingen D, Borgdorff MW, Haas    PE, Sebek MM, Veen J, Dessens M, et al. Molecular epidemiology of tuberculosis    in the Netherlands: a nationwide study from 1993 through 1997. <i>J Infect Dis.</i>    1999;180(3):726-36. DOI: 10.1086/314930.    ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000056
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!60
!v701!56
!v709!text
!v708!58
!v704!<br>   <a name="backc"></a><a href="#topc">c</a> Barnes PF, Cave MD. Molecular epidemiology    of tuberculosis. <i>N Engl J Med.</i> 2003;349(12):1149-56. DOI: 10.1056/NEJMra021964.    ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000057
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!61
!v701!57
!v709!text
!v708!58
!v704!<br>   <a name="backd"></a><a href="#topd">d</a> Dados epidemiol&oacute;gicos informados    pelo Minist&eacute;rio da Sa&uacute;de.    ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
!ID 0000058
!v004!v45n5
!v702!V:\SciELO\serial\rsp\v45n5\markup\ITss.htm
!v705!S
!v706!p
!v700!62
!v701!58
!v709!text
!v708!58
!v704!<br>   <a name="backe"></a><a href="#tope">e</a> Dados epidemiol&oacute;gicos informados    pelo Sistema de Vigil&acirc;ncia TBMDR - Fiocruz - Centro de Refer&ecirc;ncia    Professor Helio Fraga.</font></p>     ^cY
!v003!ITss.htm
!v9999!../bases-work/rsp/rsp
!v936!^i0034-8910^y2011^o5
!v002!S0034-8910(11)04500525
!v882!^v45^n5
!v880!S0034-89102011000500025
